| Kang, Yoon-Koo |
PRODIGY, NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer |
|
|
| Completed | 3 | 530 | RoW | Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) | Sanofi | Gastric Cancer | 01/19 | 12/21 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT01935778: Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH |
|
|
| Recruiting | 3 | 286 | RoW | Docetaxel and capecitabine and oxaliplatin, docetaxel/xeloda/oxliplatin, capecitabine and oxaliplatin | Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Inha University Hospital, Hallym University Medical Center | Gastric Cancer, Adjuvant Chemotherapy, XO | 06/28 | 06/28 | | |
NCT01541709: Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI |
|
|
| Active, not recruiting | 2 | 23 | RoW | imatinib | Asan Medical Center | Gastrointestinal Stromal Tumors | 12/24 | 12/24 | | |
NCT04309578: A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC |
|
|
| Recruiting | 2 | 28 | RoW | Trastuzumab, Capecitabine and Cisplatin | Asan Medical Center | Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma | 12/24 | 12/24 | | |
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab | Asan Medical Center | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 04/25 | 04/25 | | |
NCT05184803: A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer |
|
|
| Recruiting | 2 | 63 | RoW | Docetaxel injection, oxaliplatin, S-1 | Asan Medical Center | Stomach Neoplasm | 06/25 | 12/25 | | |
NCT03944304: Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
|
|
| Recruiting | 2 | 40 | RoW | Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 11/25 | 11/25 | | |
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 134 | US, RoW | SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo | Coherus Biosciences, Inc. | Hepatocellular Carcinoma | 05/25 | 05/26 | | |
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 74 | Canada, US, RoW | ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine | Jazz Pharmaceuticals | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | 07/25 | 07/25 | | |
NCT05385549: 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk |
|
|
| Recruiting | 2 | 35 | RoW | Imatinib Mesylate | Asan Medical Center | Gastrointestinal Stromal Tumors | 04/30 | 04/30 | | |
| Recruiting | 1/2 | 42 | US, RoW | YN968D1, Apatinib | Bukwang Pharmaceutical, Co., Ltd., LSK BioPartners Inc. | Cancer Patients With Solid Tumors | 06/15 | 08/15 | | |
| Active, not recruiting | 1/2 | 175 | Europe, US, RoW | BDC-1001, Nivolumab, Opdivo | Bolt Biotherapeutics, Inc., Bristol-Myers Squibb | HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer | 01/25 | 01/26 | | |
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers |
|
|
| Completed | 1 | 112 | Canada, US, RoW | ZW49 | Zymeworks BC Inc. | HER2-expressing Cancers | 09/24 | 10/24 | | |
| Recruiting | 1 | 260 | US, RoW | CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi® | Coherus Biosciences, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 12/25 | 08/26 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Park, Sun Yong |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy |
|
|
| Recruiting | 2 | 77 | RoW | Lazertinib, LECLAZA | Sung Yong Lee, Yuhan Corporation | Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer | 03/26 | 03/26 | | |
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
| Recruiting | N/A | 12000 | RoW | | Seoul National University Hospital, Astellas Pharma Inc | Kidney Transplant Rejection | 07/24 | 08/24 | | |
NCT05597683: Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy |
|
|
| Recruiting | N/A | 50 | RoW | Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block) | Gangnam Severance Hospital | Cytoreductive Surgery, Hyperthermic Intra-peritoneal Chemotherapy, Peritoneal Cancer | 12/24 | 01/25 | | |
NCT05716672: Impact of Lazertinib Dose Modification on Effectiveness and Safety |
|
|
| Not yet recruiting | N/A | 200 | RoW | Lazertinib, LECLAZA | Pusan National University Hospital, Yuhan Corporation | Non-small Cell Lung Cancer | 12/25 | 12/25 | | |
NCT05804786: Prospective Cohort of Diagnostic Bronchoscopy for Peripheral Lung Lesions |
|
|
| Recruiting | N/A | 1240 | RoW | Guided bronchoscopy, Device: Spin Thoracic Navigation System, Device: Radial EBUS probe | Seoul National University Bundang Hospital | Lung Cancer | 07/27 | 07/27 | | |
